Análisis de la acción NewAmsterdam Pharma Company NV (NAMS)NAMSNewAmsterdam Pharma Company NV

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

NewAmsterdam Pharma is not a good buy right now due to significant financial losses and negative market sentiment. The stock is currently priced at $19.83, down 43.66% year-to-date, and has an RSI of 25.93, indicating it is oversold. The company reported a net loss of $64.1 million in Q2 2026, a substantial increase from previous losses, which raises concerns about its financial health and market competitiveness. Additionally, insider selling has increased by 113.69%, suggesting a lack of confidence from those closest to the company. The main risk is the forward P/E ratio of 119.05, indicating high valuation expectations that may not be met given the current financial performance.